Teradyne (TER)
NASDAQInformation TechnologySemiconductorsSnapshot 2026-09-04
NASDAQInformation TechnologySemiconductorsSnapshot 2026-09-04
QuarterlyIQ Insights · TER
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-09-06. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $357 TER trades at 46× p/e, below its 47× p/e peer median, but our blended $281 fair value sits below the price. We hold it with low confidence: our number sits well below the analyst range. Analysts target $397–$550. Note: our $281 fair value sits below the entire analyst range ($397–$550). The flat-multiple read looks rich, but earnings are inflecting up — trailing growth is accelerating and forward estimates confirm — so we've softened our read rather than brand an accelerating name expensive. Even valued only for durable growth at sustainable margins, it's worth about $379 — above today's price, so the premium reflects that growth case, not pure multiple expansion. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $455.50 | — | — | Analyst | medium |
| dcf fcfe | 12M | $114.17 | — | — | Hist. CAGR | medium |
| dcf fcff | 12M | $116.39 | — | — | Hist. CAGR | medium |
| graham number | 12M | $61.69 | — | — | TTM | medium |
| Peer EV/EBITDA |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$397.00 – $550.00 (median $455.50) · 8 analysts · as of 2026-07-30
Only weak execution quality — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price you pay about 583% over what the business is worth with no growth; closing that gap needs roughly 10.7 years of the forecast growth to come through. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $4.63/sh owner earnings.
Roughly priced in line with peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| 12M |
| $283.68 |
| 34.8 |
| 8.09 |
| TTM |
| medium |
| Peer P/FCF | 12M | $239.49 | 47.2 | 5.07 | TTM | medium |
| Peer P/E | 12M | $549.50 | 47.2 | 11.65 | TTM | medium |
| Peer P/S | 12M | $130.03 | 4.6 | 28.31 | TTM | medium |
| PEG | 12M | $167.87 | 14.4 | 11.65 | TTM | medium |
| residual income | 12M | $40.06 | — | — | TTM | medium |
| triangulated | 12M | $387.12 | 47.2 | 8.21 | Triangulated | medium |
| Peer P/FCF | 3Y | $364.24 | 47.2 | 7.71 | Hist. CAGR(prov.) | low |
| Peer P/E | 3Y | $726.72 | 47.2 | 15.41 | Analyst | low |
| Peer P/S | 3Y | $233.02 | 4.6 | 50.73 | Analyst | low |
| PEG | 3Y | $222.01 | 14.4 | 15.41 | Analyst | low |
| Peer P/FCF | 5Y | $481.71 | 47.2 | 10.20 | Hist. CAGR(prov.) | medium |
| Peer P/E | 5Y | $961.09 | 47.2 | 20.38 | Analyst | medium |
| Peer P/S | 5Y | $308.17 | 4.6 | 67.09 | Analyst | medium |
| PEG | 5Y | $293.61 | 14.4 | 20.38 | Analyst | medium |